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DObjective: The data on echocardiographic evaluation of mitral durability after rheumatic mitral repair is scarce.
Methods:A total of 193 patients (mean age, 39.4 12.8 years; 154 females) who underwent mitral valve repair
for rheumatic valve disease from 1997 to 2010 were included in the study. A Maze operation was performed in
90.3% (n ¼ 102) of the patients with atrial fibrillation (n ¼ 113). Survival, valve-related complications, and
echocardiographic data were evaluated.
Results:Mitral regurgitation was the predominant disease in 75.6% of patients (n ¼ 146). There was one early
death (0.5%) . During the mean follow-up period of 76.7  45.6 months, there were 9 late deaths and 5 mitral
reoperations. Valve-related, event-free survival at 10 years was 85.5% 3.3%. In serial postoperative echocar-
diographic evaluations (mean follow-up duration, 53.7  43.5 months), 40 patients showed either mitral regur-
gitation (>mild; n ¼ 31) or mitral stenosis (mitral valve area 1.5 cm2; n ¼ 9). At 10 years, 66.4%  5.4% of
the patients did not have moderate to severe mitral dysfunction. By multivariate analysis, no Maze operation for
atrial fibrillation was an independent predictor of mitral dysfunctions (hazard ratio, 3.72; 95% confidence in-
terval, 1.47-9.42; P ¼ .005), whereas the presence of hypertension had borderline significance (hazard ratio,
3.15; 95% confidence interval, 0.96-10.38; P ¼ .059).
Conclusions:Although rheumatic mitral repair showed excellent long-term clinical outcomes, a significant pro-
portion of patients experienced moderate to severe mitral dysfunctions postoperatively. Atrial fibrillation with-
out a Maze procedure increased significantly the risks of mitral dysfunctions and adverse outcomes. Therefore,
routine performance of a Maze procedure is warranted in the presence of atrial fibrillation whenever possible.
(J Thorac Cardiovasc Surg 2014;147:247-53)Rheumatic mitral valve (MV) disease has a complex pathol-
ogy that affects each level of the annulus, leaflet, and
subvalvular apparatus, making it necessary to perform com-
prehensive repairs for each lesion in individual patients.1
With the development of mitral reconstructive techniques
during the past few decades,2-5 several studies have
demonstrated that MV repair is superior, in terms of
increasing survival and decreasing valve-related events, to
valve replacement for patients with degenerative mitral dis-
ease.6-13
However, the long-term durability of rheumatic mitral re-
pair remains questionable because rheumatic MV disease is
a progressive lesion and there is the possibility of relapse
even after successful repair. Previous studies have
reported the durability of mitral repair based on the rate
of reoperation.7,8 However, patients who experiencee Department of Thoracic and Cardiovascular Surgery, Asan Medical Center,
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The Journal of Thoracic and Casignificant MV dysfunctions do not necessarily undergo
valve reoperation, so any assessment of MV durability
based only on reoperation would likely underestimate the
rate of overall MV dysfunction. Although there are a few
reports of MV dysfunctions after mitral repair based on
echocardiographic evaluations, these studies focused
only on recurrent mitral regurgitation (>grade 2)
without consideration of mitral stenosis.5,14 Therefore,
a quantitative evaluation of echocardiographic evaluations
of MV function following valve repair that considers both
mitral stenosis and mitral regurgitation is important.
Therefore, we sought to evaluate the long-term results of
MV repair in patients with rheumatic MV disease. We also
sought to determine the risk factors associated with the out-
comes, especially MV dysfunctions that take into account
both mitral stenosis and regurgitation.
METHODS
Patients
From January 1997 to June 2010, a total of 1699 patients underwentMV
surgery for rheumatic mitral disease at Asan Medical Center, Seoul, South
Korea. Of these patients, 378 underwent mitral repair. Patients with asso-
ciated valve lesions, coronary artery diseases, diseases of the aorta, or peri-
cardial diseases were excluded. Patients with a previous cardiac surgery
were also excluded. However, patients who had associated incidental cor-
onary lesions (ie, 1-vessel disease) or had undergone concomitant tricuspid
repair were not excluded. Based on these guidelines, 193 patients whordiovascular Surgery c Volume 147, Number 1 247
Abbreviations and Acronyms
AF ¼ atrial fibrillation
CI ¼ confidence interval
HR ¼ hazard ratio
MV ¼ mitral valve
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study. This study was approved by our institutional review board, which
waived the requirement for informed patient consent based on the retro-
spective nature of the study.
Surgical Procedures
A median sternotomy approach was used for most patients (124/193,
64.2%), and a minimally invasive approach with either the AESOP 3000
system (Automated Endoscope System for Optimal Positioning; Computer
Motion, Inc, Santa Barbara, Calif) or the da Vinci system (Intuitive Surgi-
cal, Inc, Sunnyvale, Calif) was used for the more recent patients (69/193,
35.8%). Conventional ascending aorta and bicaval cannulations were
used for the sternotomy approach, and the minimally invasive approach in-
volved peripheral cannulations through the right internal jugular vein, right
femoral vein, and right femoral artery. Moderately hypothermic cardiopul-
monary bypass was used, and myocardial protection was achieved with
cold or tepid blood cardioplegia. After aortic crossclamping, a longitudinal
right-sided left atriotomy was the conventional approach. Mitral valve re-
pairs were performed according to the pathology of each level of the annu-
lus, leaflet, and subvalvular apparatus, as described previously.9 Details of
the MV repair techniques are summarized in Table 1. The Maze procedure
was performed using either a classic cut-and-sew Cox-Maze III (n¼ 11) or
a modified Cox-Maze III procedure (n¼ 91; cryoablation in 73, microwave
in 18). Specifically, during the minimally invasive surgery using either the
AESOP or the da Vinci system, we performed cryoablation using a flexible
probe (SurgiFrost; Medtronic, Minneapolis, Minn) via a right anterolateral
minithoracotomy that ranged from 4 to 6 cm. The lesion sets for the
modified Cox-Maze III procedure have been described previously.15,16
The surgery was performed by the same surgeon.
Follow-up
Follow-up patient data were obtained from hospital records, clinical
visits, and telephone interviews through June 2011. Data on vital status
and date of death were obtained from the Korean national registry of vital
statistics. Follow-up transthoracic echocardiographic evaluations were
generally performed at 6-month intervals during the first year and every
2 years thereafter. Postoperatively, rhythms in patients were monitored
daily using standard 12-channel surface electrocardiography. Follow-up
electrocardiograms were performed at 3- to 6-month intervals during the
first 2 years and every year thereafter. An episode of atrial fibrillation
(AF), atrial tachycardia, or atrial flutter beyond the initial blanking period
of 3 months was defined as a late AF event if it had a duration of 30 sec-
onds by monitoring. Early mortality was defined as death within 30 days of
surgery. Deaths were classified as cardiac or noncardiac on the basis of
medical records. The definition of valve-related events was based on the
guidelines for reporting mortality and morbidity after cardiac valve
interventions.17
Echocardiography
Two-dimensional and Doppler echocardiographic examinations were
performed in all patients using either a Hewlett-Packard Sonos 2500 or
5500 imaging system equipped with a 2.5-MHz transducer (Hewlett-Pack-
ard, Andover, Mass). Preoperative echocardiography was performed in all
patients<2 months prior to surgery. Mitral regurgitation was graded as248 The Journal of Thoracic and Cardiovascular Surgeither moderate (0.2 cm2  effective regurgitant orifice area< 0.4 cm2)
or severe (effective regurgitant orifice area 0.4 cm2). Mitral valve areas
were estimated using the pressure half-timemethod. Significant pulmonary
hypertension was defined as a tricuspid regurgitation peak velocity>3.4/
msec, equal to a pulmonary artery pressure>50 mmHg. Postoperative sig-
nificant MV dysfunctions were defined as follows: (1) mitral regurgitation
>mild or (2) mitral stenosis defined by an MV area 1.5 cm2.
Statistical Analysis
Categoric variables are presented as frequencies and percentages, and
continuous variables are expressed as means  SD or as medians and
ranges. Kaplan-Meier curves were used to delineate overall survival;
valve-related, event-free survival; and freedom from mitral dysfunction.
Stratified survival curves were plotted to determine unadjusted differences
for variables of interest (log-rank test). For multivariate analyses, the Cox
proportional hazards model was used to determine the association of base-
line characteristics with time to major adverse events (death- or valve-
related complications) or MV dysfunction. Prespecified covariates (Table
1 and Table 2) and the presence of postoperative AF were included in
this analysis. Variables with a probability value<0.20 in univariate analy-
ses were candidates for analyses with the multivariate Cox proportional
hazards model. Results were expressed as hazard ratios (HRs) with 95%
confidence intervals (CI). P values<.05 were considered significant. For
further verification of the results of Cox regression analysis, the model
was validated in 1000 bootstrap samples. SPSS version 18.0 (SPSS, Inc,
Chicago, Ill) was used for all statistical analyses.RESULTS
Baseline Characteristics
The mean age of patients at surgery was 39.4  12.8
years, and 79.8% (n¼ 154) were female. Forty-two percent
of patients (n ¼ 81) were categorized as New York Heart
Association functional class III or IV, and mitral regurgita-
tion was the predominant disease in 75.6% of patients
(n¼ 146). A Maze operation was performed concomitantly
with MV repair in 90.3% (n ¼ 102) of patients with AF
(n ¼ 113; Table 2).Early Outcomes
There was 1 early death (0.5%). This patient died of un-
known causes 30 days after discharge. There were 19 cases
of early postoperative complications, including postopera-
tive bleeding in 9 patients (4.7%), pericardial effusion in
2 patients (1.0%), sick sinus syndrome or complete atrio-
ventricular block in 3 patients (1.6%), and wound problems
in 5 patients (2.6%).Late Outcomes
Clinical follow-up was 99% (n ¼ 191) with a mean
follow-up duration of 76.7  45.6 months. There were 9
late deaths, of which 4 were patients who died of a cardio-
vascular cause. The causes of cardiovascular-related deaths
included unknown origin in 2 patients, congestive heart fail-
ure in 1 patient, and a pseudo-aneurysm rupture of the as-
cending aorta 233 days after the initial surgery in 1
patient. Noncardiovascular causes of death were malig-
nancy in 4 patients and meningitis in 1 patient. Overall,ery c January 2014
TABLE 1. Surgical techniques
Technique No. of cases (%)
No. of patients 193
Surgical approach
Median sternotomy 124 (64.2)
Minimally invasive approach 69 (35.8)
Mitral valve repair
Annuloplasty
Rigid, complete ring 56 (29.0)
Semirigid, complete ring 76 (39.4)
Flexible, complete ring 12 (6.2)
Flexible, partial ring 12 (6.2)
Sliding annuloplasty 3 (1.6)
Leaflet repair
Commissurotomy or leaflet mobilization 139 (72.0)
Leaflet extension or augmentation 18 (9.3)
Triangular or quadrangular resection 9 (4.7)
Subvalvular apparatus repair
Chordae
Fenestration 1 (0.5)
Shortening 1 (0.5)
Transfer 5 (2.6)
Transposition 2 (1.0)
New chordate formation 58 (30.1)
Resection 16 (8.3)
Papillary muscle splitting 66 (34.2)
Tricuspid valve repair
Ring annuloplasty 39 (20.2)
Suture annuloplasty 29 (15.0)
TABLE 2. Baseline characteristics of all patients
Characteristic No. of cases (%) or mean ± SD
No. of patients 193
Age, years 39.4  12.8
Female gender,% 154 (79.8)
NYHA functional class
I 1 (0.5)
II 110 (57.0)
III 70 (36.3)
IV 11 (5.7)
Diabetes mellitus 5 (2.6)
Hypertension 7 (3.6)
One-vessel coronary disease 3 (1.6)
Atrial fibrillation 113 (58.5)
Maze procedure* 102 (90.3)
Diagnosis of MV disease
Predominant MS 16 (8.3)
Predominant MR 146 (75.6)
Mixed MSR 31 (16.1)
Echocardiographic data
Left atrial size, mm 57.5  10.1
LV end-systolic dimension, mm 41.1  7.2
LV end-diastolic dimension, mm 60.6  9.0
LV ejection fraction,% 57.7  9.8
Tricuspid regurgitation>grade 2 45 (23.3)
Significant pulmonary hypertension 15 (7.8)
SD, Standard deviations; NYHA, New York Heart Association; MV, mitral valve;
MS, mitral stenosis; MR, mitral regurgitation; MSR, Mitral stenoregurgitation;
LV, left ventricle. *The number of patients with atrial fibrillation.
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92.2%  2.6%, respectively. During the follow-up period,
there were 10 valve-related events, including thromboem-
bolic events in 3 patients, MV reoperation in 5 patients,
and bleeding complications secondary to anticoagulation
in 2 patients. All the reoperations were MV replacements.
All the thromboembolic events were cerebrovascular acci-
dents that occurred after>1 year. There were no cases of in-
fective endocarditis. The 5- and 10-year freedom from
reoperation rate was 97.5%  1.2% and 96.7%  1.5%,
respectively (Figure 1). Overall valve-related, event-free
survival at 5 years and 10 years was 90.3%  2.3% and
85.5%  3.3%, respectively. These event-free survival
rates were influenced negatively by postoperative late AF
(P ¼ .009, Figure 2). In the Cox proportional hazards
model, postoperative late AF was the only independent pre-
dictor of decreased event-free survival (HR, 3.18; 95% CI,
1.27-7.67; P ¼ .014). The 10-year freedom from late AF
was 95.9%, 77.0%, and 27.3% in normal sinus rhythm at
preoperative state, Maze for AF, and non-Maze for AF,
respectively (P<.001, Figure 3).Mitral Valve Dysfunctions
One hundred seventy-three patients (89.6%) were evalu-
ated with echocardiography for>6 months postoperatively.The Journal of Thoracic and CaDuring a mean echocardiography follow-up duration of
53.7 43.5 months, 40 patients (16.7%) showed either sig-
nificant mitral regurgitation (>mild; n ¼ 31) or significant
mitral stenosis (MV area, 1.5 cm2; n ¼ 9). No patient
showed a significant mixed mitral stenoregurgitation pat-
tern. Freedom from moderate to severe MV dysfunctions
at 5 years and 10 years was 83.2%  3.2% and 66.4% 
5.4%, respectively. Significant mitral dysfunctions were
found more frequently in patients who did not undergo
a Maze procedure in the presence of AF than in those who
were subjected to a concomitant Maze procedure (P¼ .014,
Figure 4). Cox multivariate analysis revealed that no Maze
operation for AF was an independent predictor of mitral
dysfunctions (HR, 3.72; 95% CI, 1.47-9.42; P ¼ .005),
whereas the presence of hypertension had borderline signif-
icance (HR, 3.15; 95% CI, 0.96-10.38; P ¼ .059; Table 3).
Postoperative mitral dysfunctions according to rhythm sta-
tus and combination of the Maze procedure are shown in
Table 4.DISCUSSION
This study demonstrated that valve repair for rheumatic
mitral disease provided excellent long-term clinical out-
comes with regard to overall survival and valve-related,
event-free survival. However, a significant proportion ofrdiovascular Surgery c Volume 147, Number 1 249
FIGURE 1. Kaplan-Meier curves of long-term outcomes for patients who were subjected to rheumatic mitral repair. (A) Overall survival. (B) Freedom
from reoperation. (C) Valve-related event-free survival. (D) Freedom from mitral dysfunctions.
Acquired Cardiovascular Disease Kim et al
A
C
Dpatients experienced moderate to severe MV dysfunctions
postoperatively. In multivariate analysis, both the presence
of hypertension and a lack of a Maze operation for AF wereFIGURE 2. Kaplan-Meier curves for valve-related, event-free survival
based on the presence of late atrial fibrillation postoperatively. NSR,
Normal sinus rhythm; AF, atrial fibrillation.
250 The Journal of Thoracic and Cardiovascular Surgindependent factors associated with increased MV
dysfunctions.
The better choice of valve procedure (repair vs replace-
ment) for long-term durability in patients with rheumatic
mitral disease remains questionable. Previous studies
showed that 82% to 92% of patients did not require a reop-
eration by 10 years after the initial procedure.8,14,18 Results
of the current study (a 10-year freedom-from-reoperation
rate of 97%) corresponded with those of previous studies
and suggest an acceptable reoperation rate.
As for durability after rheumatic mitral repair, most pre-
vious studies focused on reoperation rate and did not con-
sider postoperative mitral dysfunctions.7,8 However, the
current study detected that a significant number of
patients subjected to rheumatic mitral repair experienced
postoperative MV dysfunction despite the acceptable
reoperation rate. The rates of freedom from reoperation
and freedom from moderate to severe mitral
dysfunctions at 10 years were 97% and 66%,
respectively, showing a significant gap between the
numbers. Although analysis based on reoperation rate is
limited for evaluating actual durability of the MV after
repair, analysis that considers mitral dysfunctions mayery c January 2014
FIGURE 3. Kaplan-Meier curves for freedom from late atrial fibrillation
based on rhythm status and combination of the Maze procedure (non-Maze
for AF vsMaze for AF vs NSR).NSR, Normal sinus rhythm at preoperative
state; AF, atrial fibrillation.
TABLE 3. Univariate and multivariate analyses of mitral valve
dysfunctions
Univariate Multivariate
P
value
Hazard
ratio (95% CI)
P
value
Preoperative factors
Age .685
Female gender .792
NYHA functional class>2 .644
Diabetes mellitus .548
Hypertension .066* 3.15 (0.96-10.38) .059*
One-vessel coronary disease .630
Type of mitral valve pathology .677
Preoperative atrial fibrillation .716
Operative factors
Minimally invasive approach .371
Mitral ring annuloplasty .850
Tricuspid annuloplasty .550
No Maze procedure for AF vs
Maze procedure for AF
.006* 3.72 (1.47-9.42) .005*
Maze energy source .446
Preoperative echocardiographic data
Left atrial size>60 mm .905
LV end-systolic dimension
>40 mm
.227
LV end-diastolic dimension
>60 mm
.387
LV ejection fraction,% .758
Tricuspid regurgitation
>grade 2
.617
Significant pulmonary
hypertension
.174
CI, Confidence interval; NYHA, New York Heart Association; AF, atrial fibrillation;
LV, left ventricle. *P<.05.
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durability.
The current study found that both the presence of hyper-
tension and the lack of a Maze operation for AF were inde-
pendent factors associated with postoperative mitral
dysfunction. This study found a hazard ratio of 3.15
(P ¼ .059) for postoperative MV dysfunctions in patients
with hypertension. Although the precise mechanisms of
how hypertension affects postoperative mitral dysfunctions
are unknown, there are some data that suggest detrimental
effects of hypertension on the MV.19,20 HypertensionFIGURE 4. Kaplan-Meier curves for freedom from mitral dysfunctions
based on rhythm status and combination of the Maze procedure (non-
Maze for AF vs Maze for AF vs NSR). AF, Atrial fibrillation; NSR, normal
sinus rhythm at preoperative state.
The Journal of Thoracic and Cainterferes with atrioventricular reverse remodeling after
mitral repair and can lead to abnormal changes in
geometry such as less left atrium volume regression and
left ventricular mass regression.21 Our findings may help
to uncover the roles of hypertension on the MV.
In this study, another interesting finding was that a lack of
the Maze operation for AF was a risk factor for increased
MV dysfunction. A previous study suggested that postoper-
ative MV dysfunctions could affect late recurrence of AF.22
However, our findings provide another viewpoint on theTABLE 4. Postoperative mitral dysfunction according to rhythm
status and combination of the Maze procedure
NSR
(n ¼ 80)
AF, Maze
(n ¼ 102)
AF, non-Maze
(n ¼ 11)
P
value
Mitral regurgitation (>mild) 12 14 5 .040
Mitral stenosis (MVA of
1.5 cm2)
4 4 1 .505
Mitral dysfunctions 16 18 6 .023
NSR, Normal sinus rhythm at preoperative state; AF, atrial fibrillation; MVA, mitral
valve area.
rdiovascular Surgery c Volume 147, Number 1 251
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The rhythm status of the heart can be affected by the func-
tion of the MV and vice versa. After surgical intervention,
patients with persistent AF remain at risk for asynchronous
atrioventricular contraction. The absence of an atrial
kick may prevent normal atrial remodeling and may com-
promise the efficacy of MV repair.23 Pai and colleagues24
analyzed echocardiographic data for 62 patients with either
AF (n¼ 25) or normal sinus rhythm (n¼ 37) in 2003. They
concluded that AF blunts or eliminates the phasic changes
in mitral annular size during the cardiac cycle, and this
may have implications for the genesis and surgical correc-
tion of mitral regurgitations.24 Heart rhythm status is re-
ported to contribute to maintenance of MV function. In
a study involving 73 patients with persistent AF, echocar-
diographic assessments were performed both before and af-
ter successful electrical cardioversions of AF.25 In that
study, the restoration of the sinus rhythm resulted in a signif-
icant reduction in MR jet area. In another recent study as-
sessing MV function before and after AF ablation,
restoration of synchronous atrioventricular contraction con-
tributed to a reduction in functional compartment of mitral
regurgitation.26 These phenomena can be explained by an
underlying mechanism that dilatation of the mitral annulus
secondary to AF predisposes to mitral regurgitation.27
Therefore, normalization of heart rhythm by the Maze oper-
ation for AF may be also important in the maintenance of
MV function following the surgical repair of rheumatic
MV disease. Based on our findings, we believe that a con-
comitant Maze operation should always be performed in pa-
tients with AF at the time of mitral repair. This is important
not only for cardiac rhythm correction, but also for the com-
petence of MV function.Limitations
This study was subjected to the limitations inherent in
a retrospective study using observational data of a single
center. Another limitation is that late (>6 months) postoper-
ative echocardiographic data were not available in 10.4% of
patients. Last, although lack of the Maze operation for AF
was associated strongly with postoperative mitral dysfunc-
tions, the number of patients who had not undergone the
Maze operation in the presence of AF was too small to
draw a strong conclusion.CONCLUSIONS
Despite excellent long-term clinical outcomes of rheu-
matic mitral repair, a significant number of patients experi-
enced mitral dysfunctions postoperatively. Uncorrected AF
without a concomitant Maze procedure increased signifi-
cantly the risks of mitral dysfunction and adverse outcomes.
Therefore, in the presence of AF, a concomitant Maze
procedure is suggested whenever possible.252 The Journal of Thoracic and Cardiovascular SurgReferences
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